Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 14,925 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disorders Clear all
Active, not recruiting Phase 1 Interventional

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

NCT02379377
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma, Cholangiocarcinoma, Benign Liver Tumor, Metastases to Liver
Interventions
Fluorine F 18 L-glutamate Derivative 18F-FSPG, Carbon C 11 Acetate, Positron Emission Tomography, Laboratory Biomarker Analysis, Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Biological · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Not listed No phase listed Observational

The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL)

NCT02639195
View directory record Official record
Conditions
Small Bowel Obstruction, Quality of Life, Bowel Obstruction
Interventions
Treatment
Other
Lead sponsor
Clear Passage Therapies, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 20, 2026, 8:42 AM EDT
Withdrawn Phase 4 Interventional

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir/grazoprevir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Not applicable Interventional

Microbiota-targeted Diet for Pediatric UC

NCT02922881
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ulcerative Colitis Diet (UCD)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Phase 3 Interventional Results available

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

NCT00798967
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
La Jolla, California • Washington D.C., District of Columbia • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

GEBT Telehealth Administration Usability Study

NCT04684992
View directory record Official record
Conditions
Gastroparesis
Interventions
GEBT Telehealth Administration Usability
Device
Lead sponsor
Cairn Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment

NCT00519792
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Omega DUROS device
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

NCT00909311
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-450, ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 20, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01871571
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Completed No phase listed Observational

Self-Management Assistance for Recommended Treatment (SMART) Portal

NCT01966744
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

NCT00698464
View directory record Official record
Conditions
Hepatic Cirrhosis, Alcoholism
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 20, 2026, 8:42 AM EDT
Recruiting No phase listed Observational

Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis

NCT05720663
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Standard of care
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Recruiting Not applicable Interventional

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

NCT06101277
View directory record Official record
Conditions
Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer, Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Oligoprogressive
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Recruiting No phase listed Observational

Therapeutic Endpoint in Pediatric IBD Conditions

NCT06065228
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
Interventions
AlgometRx Nociometer
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Recruiting Not applicable Interventional

Intravital Microscopy in Human Solid Tumors

NCT03823144
View directory record Official record
Conditions
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Primary Malignant Brain Neoplasm, Metastatic Sarcoma, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Resectable Colorectal Carcinoma, Resectable Liver and Intrahepatic Bile Duct Carcinoma, Resectable Pancreatic Carcinoma, Resectable Sarcoma, Stage IV Colorectal Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Liver Carcinoma, Metastatic Pancreatic Carcinoma, Resectable Brain Neoplasm, Resectable Breast Carcinoma, Resectable Gastric Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

NCT03965234
View directory record Official record
Conditions
Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Metastatic Unresectable Sarcoma, Resectable Sarcoma, Colorectal Cancer
Interventions
Cisplatin, Isolated Chemotherapeutic Lung Perfusion, Metastasectomy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents

NCT00141999
View directory record Official record
Conditions
Hepatitis
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
5 Years to 14 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 20, 2026, 8:42 AM EDT
Recruiting Phase 1 Interventional

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NCT06293898
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions
BL-M07D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy

NCT01100398
View directory record Official record
Conditions
Fatty Liver
Interventions
possible liver biopsy and serum collection
Procedure
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2010 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

NCT04102098
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06682806
View directory record Official record
Conditions
Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Interventions
PRT3789, pembrolizumab
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
West Palm Beach, Florida • Detroit, Michigan • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Phase 2 Interventional

Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment

NCT00680342
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Silymarin, Placebo
Drug · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 20, 2026, 8:42 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 20, 2026, 8:42 AM EDT